
USD
+$0.00
(+0.00%
)At Close (As of Nov 5, 2025)
$2.56B
Market Cap
-
P/E Ratio
-0.68
EPS
$138.81
52 Week High
$10.41
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $1.6B |
| Total Revenue | $1.9B |
| Cost Of Revenue | $319M |
| Costof Goods And Services Sold | $319M |
| Operating Income | $218M |
| Selling General And Administrative | $558M |
| Research And Development | $805M |
| Operating Expenses | $1.4B |
| Investment Income Net | - |
| Net Interest Income | $53M |
| Interest Income | $72M |
| Interest Expense | $18M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $54M |
| Income Before Tax | $261M |
| Income Tax Expense | $26M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $235M |
| Comprehensive Income Net Of Tax | - |
| Ebit | $279M |
| Ebitda | $333M |
| Net Income | $235M |
| Field | Value (USD) |
|---|---|
| Total Assets | $4B |
| Total Current Assets | $3.1B |
| Cash And Cash Equivalents At Carrying Value | $1.1B |
| Cash And Short Term Investments | $1.1B |
| Inventory | $750M |
| Current Net Receivables | $650M |
| Total Non Current Assets | $890M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $27M |
| Intangible Assets Excluding Goodwill | $27M |
| Goodwill | - |
| Investments | - |
| Long Term Investments | $137M |
| Short Term Investments | $252M |
| Other Current Assets | $319M |
| Other Non Current Assets | - |
| Total Liabilities | $2.4B |
| Total Current Liabilities | $732M |
| Current Accounts Payable | $214M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $27M |
| Total Non Current Liabilities | $1.7B |
| Capital Lease Obligations | $206M |
| Long Term Debt | $1.1B |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $1.3B |
| Other Current Liabilities | $343M |
| Other Non Current Liabilities | $49M |
| Total Shareholder Equity | $1.5B |
| Treasury Stock | - |
| Retained Earnings | -$4.2B |
| Common Stock | $10K |
| Common Stock Shares Outstanding | $108M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$206M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $38M |
| Capital Expenditures | $137M |
| Change In Receivables | - |
| Change In Inventory | -$395M |
| Profit Loss | - |
| Cashflow From Investment | $756M |
| Cashflow From Financing | $125M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | $235M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $1.6B |
| Total Revenue | $1.9B |
| Cost Of Revenue | $319M |
| Costof Goods And Services Sold | $319M |
| Operating Income | $218M |
| Selling General And Administrative | $558M |
| Research And Development | $805M |
| Operating Expenses | $1.4B |
| Investment Income Net | - |
| Net Interest Income | $53M |
| Interest Income | $72M |
| Interest Expense | $18M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $54M |
| Income Before Tax | $261M |
| Income Tax Expense | $26M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $235M |
| Comprehensive Income Net Of Tax | - |
| Ebit | $279M |
| Ebitda | $333M |
| Net Income | $235M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Sarepta Therapeutics, Inc. is a pioneering biopharmaceutical company based in Cambridge, Massachusetts, that focuses on the development of RNA-targeted and gene therapies for rare genetic disorders, particularly Duchenne muscular dystrophy (DMD). With an innovative pipeline and a strong commitment to addressing significant unmet medical needs, Sarepta is reshaping treatment paradigms in genetic medicine. The company's advanced scientific expertise and cutting-edge technologies position it as a leader in the biopharmaceutical sector, driving transformative therapies that have the potential to significantly improve patient outcomes.